745 related articles for article (PubMed ID: 16616932)
1. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
2. FlexE: efficient molecular docking considering protein structure variations.
Claussen H; Buning C; Rarey M; Lengauer T
J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
[TBL] [Abstract][Full Text] [Related]
3. Protein flexibility in ligand docking and virtual screening to protein kinases.
Cavasotto CN; Abagyan RA
J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
[TBL] [Abstract][Full Text] [Related]
4. Modeling and selection of flexible proteins for structure-based drug design: backbone and side chain movements in p38 MAPK.
Subramanian J; Sharma S; B-Rao C
ChemMedChem; 2008 Feb; 3(2):336-44. PubMed ID: 18081134
[TBL] [Abstract][Full Text] [Related]
5. Conformational selection of protein kinase A revealed by flexible-ligand flexible-protein docking.
Huang Z; Wong CF
J Comput Chem; 2009 Mar; 30(4):631-44. PubMed ID: 18711718
[TBL] [Abstract][Full Text] [Related]
6. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
7. Combining docking and molecular dynamic simulations in drug design.
Alonso H; Bliznyuk AA; Gready JE
Med Res Rev; 2006 Sep; 26(5):531-68. PubMed ID: 16758486
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking of balanol to dynamics snapshots of protein kinase A.
Wong CF; Kua J; Zhang Y; Straatsma TP; McCammon JA
Proteins; 2005 Dec; 61(4):850-8. PubMed ID: 16245317
[TBL] [Abstract][Full Text] [Related]
10. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function.
Taylor RD; Jewsbury PJ; Essex JW
J Comput Chem; 2003 Oct; 24(13):1637-56. PubMed ID: 12926007
[TBL] [Abstract][Full Text] [Related]
11. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
Perola E; Walters WP; Charifson PS
Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
[TBL] [Abstract][Full Text] [Related]
12. A novel lipid binding site formed by the MAP kinase insert in p38 alpha.
Diskin R; Engelberg D; Livnah O
J Mol Biol; 2008 Jan; 375(1):70-9. PubMed ID: 17999933
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D
Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758
[TBL] [Abstract][Full Text] [Related]
15. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
Badrinarayan P; Sastry GN
J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
[TBL] [Abstract][Full Text] [Related]
16. Incorporating receptor flexibility in the molecular design of protein interfaces.
Li L; Liang S; Pilcher MM; Meroueh SO
Protein Eng Des Sel; 2009 Sep; 22(9):575-86. PubMed ID: 19643976
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
[TBL] [Abstract][Full Text] [Related]
20. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
